Medicines and devices listed in the NLEM must be sold at the prices set by National Pharmaceuticals Pricing Authority (NPPA), while those i...

India has the world's highest TB burden-- 2.6 million active cases and close to 450,000 deaths each year from the infectious bacterial dise...

BPaL is a six-month, alloral, three-drug regimen that is used to treat people with highly drug-resistant forms of TB. It consists of the TB...

India alone accounts for one fourth of the global TB burden.

Tuberculosis is among one of the biggest risks in India, and kills 1.5 mn people every year.

Pretomanid, a new oral treatment is a shorter more convenient option for people with extensively drug resistant (XDR) TB. The dossier for g...

Pretomanid is the third TB drug to have been approved by the USFDA in the last 40 years.

Pretomanid, a new chemical entity, was under development since 2002 by the TB Alliance.

To ensure the drug is accessible to all, MSF called on J&J to issue a non-exclusive license to the Medicines Patent Pool to allow for price...

J&J said India is eligible for the lowest global price and that it is working on a sustainable access strategy.

The 1997 Nobel winner in chemistry, who was one of the speakers at the Lindau Nobel Laureates meeting, said clinical data showed that the d...

India's dependency on charity from global drug makers is making it hard for patients to access new antibiotic drugs such as bedaquiline and...

The TB bacterium is cunning and is able to survive according to the researchers due to its ability to sense and adapt to its host's environ...

Stoffels, who is also worldwide chairman of the US drug major’s pharmaceuticals group, was in India recently to take stock of company’s ope...